Roughly 1 in 10 Canadians use well being providers yearly for temper and anxiousness issues, based on a Canadian authorities report, Temper and Nervousness Issues in
New, efficient therapies for temper and anxiousness issues have been developed with confirmed advantages to sufferers, together with intravenous ketamine (IV-Ket) and neurostimulation. These therapies require brief visits to a clinic usually lasting 2 hours or much less. NeonMind’s analysis reveals there’s a lack of obtainable and conveniently situated clinics offering these therapies. NeonMind’s
‘By partnering with SRx Well being Options and BioScript, we will leverage their established clinic community and operational excellence in specialty medical therapies to introduce our psychological well being therapies in an expedient and capital environment friendly method and importantly, working with an infrastructure that allows scaling’ stated
NeonMind plans to launch its first therapy location this summer time in
Initially NeonMind clinics will provide IV-Ket, a validated therapy that was not too long ago added to the Canadian pointers. IV-Ket requires a licensed clinic setup and a workforce of specifically educated healthcare professionals which most medical clinics can’t obtain and subsequently should not in a position to present this therapy. NeonMind is closing the therapy hole by providing medical docs a trusted referral accomplice for his or her sufferers to get entry to IV-Ket.
NeonMind’s inaugural specialty psychological well being clinic might be situated at 89 Queensway West, Suite 604,
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug growth of psychedelic compounds with two lead psilocybin-based drug candidates focusing on weight problems; and (ii) a medical providers division targeted on launching specialty psychological well being clinics that combine psychedelic therapeutics into conventional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug growth packages focusing on weight problems. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist on the serotonin 5- HT2A receptor, which is concerned within the hallucinogenic impact of psychedelics. The Firm’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist on the 5-HT2C receptor, which controls urge for food.
NeonMind and its strategic companions are constructing NeonMind-branded specialty psychological well being clinics in
President & Chief Govt Officer
The Canadian Securities Alternate has not reviewed, authorized nor disapproved the contents of this information launch.
Cautionary Assertion Relating to Ahead-Trying Statements
Sure statements contained on this press launch represent forward-looking info. These statements relate to future occasions or NeonMind’s future efficiency. The usage of any of the phrases ‘may’, ‘count on’, ‘consider’, ‘will’, ‘projected’,’estimated’ and comparable expressions and statements regarding issues that aren’t historic information are supposed to establish forward-looking info and are primarily based on NeonMind’s present perception or assumptions as to the result and timing of such future occasions. Precise future outcomes could differ materially. Specifically, NeonMind’s drug growth plans, its skill to retain key personnel, and its expectation as to the event of its mental property and different steps in its preclinical and medical drug growth represent forward-looking info. Precise outcomes and developments could differ materially from these contemplated by forward-looking info. Readers are cautioned to not place undue reliance on forward-looking info. The statements made on this press launch are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly replace or revise any forward-looking info, whether or not because of new info, future occasions or in any other case, besides as could also be expressly required by relevant securities legal guidelines.